Evolus sells cosmetic injectables that people pay for out of pocket, so demand can drop quickly when everyday budgets tighten. The business is trying to expand beyond its main wrinkle treatment with new fillers and future launches, but a soft market and potential import costs could slow the payoff.Read more
Evolus is trying to reduce its reliance on a single flagship wrinkle-treatment by pushing into more countries and rolling out new products that could broaden its customer base. The big question is whether demand for cosmetic procedures rebounds soon enough—and whether newer launches turn into steady repeat sales rather than a short-lived early spike.Read more
Catalysts About Evolus Evolus is a performance beauty company focused on cash pay injectable aesthetics, including neurotoxin and hyaluronic acid filler products. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
